COMPASS Pathways plc (NASDAQ:CMPS) Short Interest Up 21.7% in February

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 5,440,000 shares, an increase of 21.7% from the January 31st total of 4,470,000 shares. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is presently 5.3 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CMPS. Virtus ETF Advisers LLC grew its position in COMPASS Pathways by 21.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock worth $61,000 after buying an additional 2,840 shares in the last quarter. Conservest Capital Advisors Inc. grew its holdings in shares of COMPASS Pathways by 28.9% during the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after purchasing an additional 3,000 shares in the last quarter. Kennedy Capital Management LLC increased its position in shares of COMPASS Pathways by 22.8% during the fourth quarter. Kennedy Capital Management LLC now owns 33,976 shares of the company's stock valued at $128,000 after purchasing an additional 6,297 shares during the period. Barclays PLC raised its stake in shares of COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after purchasing an additional 8,718 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of COMPASS Pathways by 15.4% in the fourth quarter. Point72 Asset Management L.P. now owns 67,999 shares of the company's stock valued at $257,000 after purchasing an additional 9,099 shares in the last quarter. Institutional investors own 46.19% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently weighed in on CMPS. Stifel Nicolaus started coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 price target for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 target price on shares of COMPASS Pathways in a research note on Wednesday, January 15th. HC Wainwright restated a "buy" rating and set a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group reduced their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $21.83.

COMPASS Pathways Stock Performance

Shares of COMPASS Pathways stock traded down $0.20 during trading on Monday, reaching $3.54. The company's stock had a trading volume of 1,920,521 shares, compared to its average volume of 726,264. COMPASS Pathways has a one year low of $3.17 and a one year high of $11.33. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a market cap of $328.06 million, a price-to-earnings ratio of -1.61 and a beta of 2.29. The business's fifty day moving average price is $4.04 and its 200-day moving average price is $5.12.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, equities research analysts predict that COMPASS Pathways will post -2.33 earnings per share for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.